Hepatitis due to Reactivation of Hepatitis B Virus in Endemic Areas Among Patients With Hepatitis C Treated With Direct-acting Antiviral Agents

详细信息    查看全文

• 作者：Cheng Wang^&lowast ; ; ^&Dagger ; ; Dong Ji^§ ; ; ^‖ ; Jing Chen^&lowast ; ; Qing Shao^§ ; ; Bing Li^§ ; ; Jialiang Liu^§ ; ; Vanessa Wu^&lowast ; ; April Wong^&lowast ; ; Yudong Wang^&lowast ; ; Xiaoyong Zhang^&Dagger ; ; Lei Lu^&lowast ; ; Chris Wong^¶ ; ; Stella Tsang^¶ ; ; Zheng Zhang^# ; Jian Sun^&Dagger ; ; Jinlin Hou^&Dagger ; ; Guofeng Chen^§ ; ; George Lau^&lowast ; ; ^§ ; ; ^# ; ^{gkklau@netvigator.com}
• 关键词：Therapy ; Risk Factor ; Coinfection ; Prognostic Factor
• 刊名：Clinical Gastroenterology and Hepatology
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：15
• 期：1
• 页码：132-136
• 全文大小：210 K
• 卷排序：15

文摘

Hepatitis due to reactivation of hepatitis B virus (HBV) has been reported in patients treated with direct-acting antiviral (DAA) agents for chronic hepatitis C virus infection. We performed an observational study to determine the incidence of and factors associated with hepatitis in 327 patients receiving pan-oral DAA agents for HCV infections in areas endemic for HBV in China. Ten patients were positive for hepatitis B surface antigen (HBsAg), and 124 patients had occult HBV infection. HBV reactivation was determined by measuring HBV DNA and HBsAg status in serial serum samples collected every 2 weeks during DAA treatment and then every 4 weeks after treatment until week 12. In the total study population, 10 patients (3.1%) had hepatitis; 3 cases were associated with HBV reactivation (1 case not in the icteric phase, 1 case in the icteric phase, and 1 case with liver failure) and 7 from other causes. Testing positive for HBsAg before DAA treatment was a strong risk factor for developing hepatitis during treatment (hazard ratio, 15.0; P < .001).